慢性阻塞性肺疾病(COPD)相关生物学标志物研究进展  

The Progress of Related Biomarkers in COPD

作　　者：刘蕾[1] 李宇航[1] 

机构地区：[1]北京中医药大学基础医学院,北京100029

出　　处：《中华中医药学刊》2010年第9期1857-1861,共5页Chinese Archives of Traditional Chinese Medicine

基　　金：国家重点基础研究发展计划(973计划)项目(2009CB522704)

摘　　要：目前,可用于评估慢性阻塞性肺疾病(COPD)患者病情和临床疗效的标志物有限。被视为金标准的1s用力呼气量(FEV1)对于有些患者而言依从性较差。临床上希望能够探索新的指标,对于提高COPD诊断水平、揭示发病机制、指导治疗用药等均具有重要意义。COPD生物学标志物是指任何能反映疾病进程的分子或其他物质(如细胞、组织等),它应与COPD病理生理改变、炎症反应、肺实质破坏等过程相关。目前,COPD生物学标记物的研究已逐步成为热点,从COPD生物学标记物的研究概况、生物学指标与临床指标间相关组合模式探讨及COPD生物学标志物研究趋势等3个方面进行阐述。Currently the markers which can be used to evaluate the patient＇s condition and clinical efficacy are limited. The forced expiratory volume in one second （FEV1）, considered as the gold standard in terms of compliance for some patients is poor. It is of great significance to explore new targets for improving COPD diagnosis, revealing disease mechanisms, to guide therapeutic drugs and so on.COPD biomarker is any molecular or other substances （such as cell, tissue, etc）,which can reflect the disease process, it should be related with the pathophysiological changes, inflammation, and other process-related substance with lung damage in COPD. Accordingly, there are large-scale studies presently underway to identify novel biomarkers in COPD. In this article, we discuss the current barriers of biomarker discovery and propose possible criteria and methods for developing novel biomarkers in COPD.

关 键 词：COPD 生物标记物 

分 类 号：R563[医药卫生—呼吸系统]